Skip to content

Antenatal Multiple Micronutrient Supplementation (MMS) in Indonesia

Implementation Research to Accelerate Multiple Micronutrient Supplementation During Pregnancy in Indonesia

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06225791
Enrollment
5384
Registered
2024-01-26
Start date
2023-12-25
Completion date
2025-03-17
Last updated
2025-06-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nutrient Deficiency

Keywords

multiple micronutrient supplementation (MMS), pregnancy, behavior change, packaging, antenatal care (ANC)

Brief summary

The objective of this research is to understand how antenatal multiple micronutrient supplements (MMS) can be effectively implemented and scaled within the Indonesian national health system context to support improved maternal nutrition and birth outcomes. Formative research has been conducted to design the implementation strategies that will be tested in this second phase of the study. The objectives are to: * Examine different MMS delivery strategies (i.e., packaging strategies and behavior change communication (BCC) strategies) in relation to MMS adherence. * Assess acceptability, feasibility, fidelity, and coverage of MMS program implementation within antenatal care services (ANC)

Detailed description

The study will utilize qualitative and quantitative methods to: * Test different MMS delivery strategies (bottle count \[90 vs. 180 tablets\] and communication strategies \[BCC vs. expanded BCC vs. MMS orientation only\]) for enhancing supplementation consumption - measured as coverage and adherence. * Assess acceptability, feasibility, and fidelity of MMS program implementation within antenatal care services (ANC) More specifically, the investigators will implement and evaluate different MMS packaging (90 count bottle vs 180-count bottle) strategies and behavior change communication (BCC) strategies. The 3 BCC approaches are further described below. * BCC, BCC without Interpersonal Communication (IPC) strategy is a briefer more basic approach that hopes to improve health care providers knowledge about MMS and the providers ability to communicate with pregnant women. This approach will be rolled out by training one district-level facilitator in each district to become a trainer who will be responsible for training health providers in the corresponding study sub-districts. * Expanded BCC ('BCC with Interpersonal Communication \[IPC\]') needs more intensive training of master trainers to train health care providers and focuses more on the counselling skills portion. The BCC without IPC is more feasible to implement within the existing system, the investigators anticipate that the BCC with IPC achieve better behavior change results. * MMS Orientation: Women in the control group will receive the existing standard of counselling care. The providers will not be given any sort of training on counselling. Due to the fact that MMS is a new product that the providers will be providing pregnant women, all health care providers will receive a standard MMS orientation so providers are comfortable with the new supplement. The study will be conducted in 25 districts representing the western, central, and eastern regions of Indonesia, Indonesia's socio-cultural diversity, and varying capacity of ANC systems across districts. After selection, the 25 districts were divided to receive high-intensity (8 districts), moderate-intensity (5 districts), or low-intensity (12 districts) evaluation activities with those exposed to high-intensity evaluation efforts having comprehensive individual-level data collected by study employed data collectors while the low-and moderate-intensity district data collection efforts are being done within the context of the existing health system. 1. High intensity evaluation areas (8 districts) Evaluation of MMS acceptability, coverage, adherence, feasibility, and fidelity will include data collection from health professionals and pregnant women by study data collectors, and by ANC monitoring activities. 2. Moderate intensity evaluation areas (5 districts) Evaluation of ANC records with aggregate coverage and adherence numbers will be shared with investigators. In addition, data collectors will collect MMS acceptability, feasibility, and fidelity data within 2 of those 5 districts. 3. Low intensity evaluation area (12 districts) Evaluation of ANC records with aggregate coverage and adherence numbers will be shared with investigators. In addition, a household coverage survey will be administered in a subset of districts (n=6) post-intervention to examine MMS acceptability, adherence, coverage, and implementation feasibility and fidelity. The coverage survey will be designed after 6 months of implementation and will be submitted as a separate application to the Johns Hopkins Bloomberg School of Public Health Institutional Review Board, and a separate entry into Clinicaltrials.gov. Within the 8 high-intensity districts and 5 moderate-intensity districts that are the subject of this Clinicaltrials.gov submission, the study will utilize a three-arm cluster randomized design (with sub-district health center as the unit of randomization).

Interventions

BEHAVIORALMMS (90x2) + BCC or expanded BCC

Provision of 90-count bottles x 2, with enhanced MMS delivery strategy (5 districts with MMS orientation with BCC; 8 districts with MMS orientation with expanded BCC)

BEHAVIORALMMS (180x1) + BCC or expanded BCC

Provision of 180-count bottles x 1, with enhanced MMS delivery strategy (5 districts with MMS orientation with BCC; 8 districts with MMS orientation with expanded BCC)

Sponsors

Indonesia University
CollaboratorOTHER
Hasanuddin University
CollaboratorOTHER
Universitas Airlangga
CollaboratorOTHER
Vitamin Angels
CollaboratorUNKNOWN
Johns Hopkins Bloomberg School of Public Health
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE

Intervention model description

MMS will be implemented across 13 districts in Indonesia. In each of the 8 high-intensity evaluation districts and 5 moderate-intensity evaluation districts, 3 study arms/sub-districts have been purposively selected (total n = 24 sub-districts). * Arm/sub-district 1: Provision of 90-count bottles x 2, with standard MMS delivery strategies and MMS orientation * Arm/sub-district 2: Provision of 90-count bottles x 2, with enhanced MMS deliveries strategy (3 with MMS orientation with BCC; 5 with MMS orientation with expanded BCC) * Arm/sub-district 3: Provision of 180-count bottles x 1, with enhanced MMS delivery strategy (3 with MMS orientation with BCC; 5 with MMS orientation with expanded BCC)

Eligibility

Sex/Gender
ALL
Healthy volunteers
Yes

Inclusion criteria

for 3,360 pregnant women (PW) enrolled from 8 high-intensity evaluation districts (sample group 1) * Enrolled in ANC 1 through government health facilities. * Received MMS at ANC 1 * Gestational age at ANC 1 ≤ 20 weeks (verified by health professionals) * Consent provided to participate in the study.

Exclusion criteria

for 3,360 pregnant women (PW) enrolled from 8 high-intensity evaluation districts (sample group 1) * PW with complicated pregnancy complications (e.g., thalassemia, hemochromatosis,) * PW planning to move outside study district during study period. Inclusion Criteria for 72 PW / recently delivered women participating in in-depth interviews (IDI) only (sample group 2) * Enrolled in ANC 1 through government health facilities. * Received MMS at ANC 1 * Gestational age at ANC 1 ≤ 20 weeks (verified by health professionals) * Consent provided to participate in qualitative component of study. * Received MMS for at least 3 months. * Attended \> 2 ANC visits. * \< 4 weeks post-partum

Design outcomes

Primary

MeasureTime frameDescription
MMS Adherence (frequency)Post-enrollment up to 3 months, Post-pregnancy up to 4 weeksThe frequency of which MMS tablets are consumed by a pregnant woman. (sample group 1)
MMS Adherence (amount)Post-enrollment up to 3 months, Post-pregnancy up to 4 weeksThe number of MMS tablets (from a total possible 180 tablets) a pregnant woman consumes (sample group 1).

Secondary

MeasureTime frameDescription
Fidelity of providing MMS among Health Providers as assessed by focus group discussions6 months, 12 monthsAdministration of an observation checklist (sample group 3),measured via focus group discussions at two time points during the study (middle and end)
MMS Acceptability among Pregnant WomenPost-enrollment up to 3 months, Post-pregnancy up to 4 weeksThe proportion of pregnant women (sample group 1 and 2) who agree with domain-specific statements which reflect different aspects of MMS acceptability (MMS packaging, MMS physical properties, MMS side effects, and MMS counseling using The Theoretical Framework of Acceptability uses a 5-point Likert scale where 5 is strongly agree and 1 is strongly disagree. Score range 5-35, a higher score reflects higher acceptability.
MMS Acceptability among Health Providers assessed by focus group discussions6 months, 12 monthsHealthcare provider acceptability of MMS across multiple domains (e.g., feasibility of delivering counseling and packaging, time burden) (sample group 3). Measured via focus group discussions at two time points during the study (middle and end).

Other

MeasureTime frameDescription
Number of pregnant women being given 180 tablets of MMSMonthly up to 18 monthsMMS coverage as assessed by the number of pregnant women being given 180 tablets of MMS as compared to the estimated number of pregnant women in the population (e.g., within the 24 study sub-districts) via routine data collection from facility to district health office (aggregate data).
Number of MMS tablets consumedMonthly up to 18 monthsMMS adherence as assessed by the number of MMS tablets (from a total of 180 tablets) women who receive MMS are consuming. Routine Data Collection (aggregate data) from facility to district health office.

Countries

Indonesia

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026